ProfileGDS5678 / 1445125_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 64% 55% 54% 55% 62% 54% 55% 48% 55% 55% 52% 44% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3948854
GSM967853U87-EV human glioblastoma xenograft - Control 23.853264
GSM967854U87-EV human glioblastoma xenograft - Control 33.3859655
GSM967855U87-EV human glioblastoma xenograft - Control 43.2939754
GSM967856U87-EV human glioblastoma xenograft - Control 53.3217555
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7644662
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4400354
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3598455
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1142448
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3669255
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3628655
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2108752
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0316844
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4531557